Rostock International Parkinson's Disease Study (ROPAD)

• Research type

  Research Study

• Full title

  ROSTOCK INTERNATIONAL PARKINSON’S DISEASE STUDY LRRK2 INTERNATIONAL PARKINSON’S DISEASE PROGRAM: AN INTERNATIONAL, MULTICENTER, EPIDEMIOLOGICAL OBSERVATIONAL STUDY

• IRAS ID

  264442

• Contact name

  Nicola Pavese

• Contact email

  nicola.pavese@newcastle.ac.uk

• Sponsor organisation

  Centogene AG

• Duration of Study in the UK

  1 years, 11 months, 31 days

• Research summary

  This study contains three study objectives. The primary objective is to identify 1500 LRRK2-positive patients. The secondary objective is to identify 1500 non-LRRK2 PD patients (including a subset of ~500 patients with monogenic PD other than LRRK2). The tertiary objective is to establish biomarker in LRRK2-positive cohort. Participation in the study involves a standard history, examination, and taking of a single research blood sample. The single research blood sample will be equivalent to 30 drops of blood (less than 1 mL). This will be applied to the Dry Blood Spot (DBS) filtercard which will be sent for genetic analysis to Centogene laboratory.

• REC name

  London - South East Research Ethics Committee

• REC reference

  19/LO/0893

• Date of REC Opinion

  25 Jul 2019

• REC opinion

  Further Information Favourable Opinion